IBB News Alert Nasdaq Biotechnology Ishares (IBB) 306.20 12/04/2014

New Post Public Reply Private Reply Replies (0) Message Board

Dec 4, 2014 at 6:29 PM

Nasdaq Biotechnology Ishares (IBB) 306.20 $IBB

‘Fast Money’ Recap: Can Stocks Still Rally if Oil Prices Rebound?
at The Street - Wed Dec 03, 4:00AM CST
The trading panel discussed energy stocks, biotechs and Taser.
BIIB: 341.18 (-6.16), ABT: 45.49 (-0.19), VRTX: 118.71 (-1.47), F: 15.81 (-0.20), BMRN: 89.96 (-1.14), RRGB: 71.76 (+0.33), XOP: 49.33 (-1.67), BBRY: 10.47 (-0.45), IBB: 306.20 (-2.05), CP: 194.15 (-3.69), TASR: 24.15 (+1.29), XLE: 81.25 (-0.71), CELG: 113.63 (-0.60)

SmarTrend Watching for Potential Pullback in Shares of iShares Nasdaq Biotechnology Index After 2.08% Gain
Comtex SmarTrend(R) - Tue Dec 02, 3:54PM CST
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $303.21 to a high of $307.67. Yesterday, the shares gained 2.1%, which took the trading range above the 3-day high of $307.16 on volume of 1.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
IBB: 306.20 (-2.05)

iShares Nasdaq Biotechnology Index Set to Possibly Pullback After Yesterday's Rally of 2.08%
Comtex SmarTrend(R) - Tue Dec 02, 3:53PM CST
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $303.21 to a high of $307.67. Yesterday, the shares gained 2.1%, which took the trading range above the 3-day high of $307.16 on volume of 1.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
IBB: 306.20 (-2.05)

Energy Stocks Shake Off Plunging Oil Prices to Push the Dow to New Highs
at The Street - Tue Dec 02, 3:30PM CST
Oil prices backtrack from Monday's bounce, but energy stocks shake it off. Instead, the sector gains more than 1% after several weeks of punishing losses.
CY: 12.48 (-0.03), BIIB: 341.18 (-6.16), AVNR: 16.96 (+0.04), XOM: 94.37 (-0.58), IBB: 306.20 (-2.05), FCAU: 13.22 (-0.34), CVX: 112.28 (-1.43), XLE: 81.25 (-0.71), CODE: 29.01 (+0.15)

Biotech Weekly: Biotech From The Charts And What I'm Watching Into Year End
Daniel Ward - at Seeking Alpha - Mon Dec 01, 10:35AM CST

XBI: 178.11 (-1.37), IBB: 306.20 (-2.05), AGIO: 104.05 (+2.03), CELG: 113.63 (-0.60)

3 Biotech Stocks With Jaw-Dropping Growth Potential in 2015
George Budwell, The Motley Fool - Motley Fool - Sat Nov 29, 1:01PM CST
The biotech industry has been absolutely soaring over the past two years, fueled by a rise in drug approvals, an merger-and-acquisition frenzy, and widespread reorganizations that have helped to mitigate the impact of the so-called "patent cliff."...
JNJ: 107.56 (-0.16), FLML: 16.84 (+0.10), GERN: 3.50 (-0.10), ICPT: 138.02 (+1.02), IBB: 306.20 (-2.05)

Prepare For A Deflationary Boom?
Leo Kolivakis - at Seeking Alpha - Sat Nov 29, 10:20AM CST
Jon D. Markman of Yahoo Finance reports, Prepare for the rare "deflationary boom" : "Deflation" and "boom" are not two words that normally go together. They are almost like "sad happiness," "low-cal...
XLB: 49.81 (+0.15), QQQ: 105.37 (-0.05), XBI: 178.11 (-1.37), IBB: 306.20 (-2.05), XLK: 42.17 (unch), IWM: 116.81 (-0.56), GSG: 24.50 (-0.12), XLE: 81.25 (-0.71)

Vargatef cleared in Europe for lung cancer
Seeking Alpha - at Seeking Alpha - Fri Nov 28, 8:23AM CST

HTBX: 4.40 (-0.20), BIB: 128.92 (-1.83), INCY: 74.12 (-0.54), PFE: 31.67 (-0.08), IBB: 306.20 (-2.05), DRGS: 54.00 (unch), BIND: 6.14 (-0.58), BMY: 58.89 (-0.14), GSK: 45.89 (-0.82), ONTY: 1.73 (+0.05), ECYT: 6.16 (-0.19), BIS: 46.40 (+0.64), CLVS: 48.63 (-0.15), AZN: 73.94 (+0.12), MRK: 60.92 (+0.34), ARIA: 7.20 (-0.26), IRY: 49.05 (+0.06), IXJ: 103.43 (-0.03), FPRX: 20.65 (-0.25)

How Much Is The Biotech Industry Stretched?
Fred Piard - at Seeking Alpha - Fri Nov 28, 7:11AM CST

BIIB: 341.18 (-6.16), GILD: 101.82 (+0.94), FBT: 101.78 (-0.63), XBI: 178.11 (-1.37), IBB: 306.20 (-2.05), AMGN: 166.55 (-1.52), CELG: 113.63 (-0.60)

UniQure sets price record with Glybera
Seeking Alpha - at Seeking Alpha - Wed Nov 26, 2:33PM CST

BIS: 46.40 (+0.64), QURE: 12.64 (-0.84), BIB: 128.92 (-1.83), ALXN: 197.66 (-1.22), IBB: 306.20 (-2.05)

China mulling eliminating drug price controls
Seeking Alpha - at Seeking Alpha - Wed Nov 26, 6:17AM CST

EWH: 21.21 (-0.04), PEK: 41.80 (+1.97), CNXT: 31.21 (+0.67), KBA: 43.63 (+1.77), BIB: 128.92 (-1.83), CQQQ: 35.81 (-0.16), IBB: 306.20 (-2.05), DRGS: 54.00 (unch), CHXF: 52.82 (+1.42), YINN: 34.85 (+2.91), FXP: 44.37 (-2.81), EWHS: 28.39 (unch), PGJ: 29.27 (-0.13), FCA: 23.33 (+0.44), YAO: 28.54 (+0.66), FCHI: 51.42 (+1.38), ASHR: 34.79 (+2.58), ASHS: 37.55 (+0.96), GXC: 80.70 (+1.41), FXI: 41.51 (+1.21), XPP: 67.37 (+3.74), KWEB: 34.71 (-0.31), ECNS: 46.95 (+0.08), TAO: 21.83 (-0.09), CHNA: 32.06 (+1.90), QQQC: 22.48 (-0.07), CHIX: 15.33 (+0.55), KFYP: 66.00 (-1.53), HAO: 27.01 (+0.13), MCHI: 50.40 (+1.17), CHIM: 15.23 (unch), YANG: 12.33 (-1.19), BIS: 46.40 (+0.64), CHIQ: 13.25 (unch), CHIE: 13.75 (unch), FHK: 39.19 (-0.04), CHII: 13.58 (+0.27), YXI: 28.70 (-1.07), CN: 33.93 (+1.19)

Drug makers face pushback on pricey meds
Seeking Alpha - at Seeking Alpha - Tue Nov 25, 7:18AM CST

ABT: 45.49 (-0.19), BIIB: 341.18 (-6.16), BIB: 128.92 (-1.83), PFE: 31.67 (-0.08), AMGN: 166.55 (-1.52), IBB: 306.20 (-2.05), LLY: 72.38 (+1.25), DRGS: 54.00 (unch), GSK: 45.89 (-0.82), BMY: 58.89 (-0.14), CELG: 113.63 (-0.60), JNJ: 107.56 (-0.16), ESRX: 84.03 (-0.27), BIS: 46.40 (+0.64), MRK: 60.92 (+0.34), AZN: 73.94 (+0.12), CVS: 89.84 (+0.70), ABBV: 69.57 (+1.07), SNY: 46.75 (-1.36), IRY: 49.05 (+0.06), IXJ: 103.43 (-0.03), NVS: 95.77 (+0.11)

iShares Nasdaq Biotechnology Index Rises 1.74% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Mon Nov 24, 3:53PM CST
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $295.23 to a high of $300.15. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $298.75 on volume of 1.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
IBB: 306.20 (-2.05)

After Yesterday's Rally of 1.74% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon Nov 24, 3:52PM CST
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $295.23 to a high of $300.15. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $298.75 on volume of 1.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
IBB: 306.20 (-2.05)

Histogenics on deck for IPO
Seeking Alpha - at Seeking Alpha - Mon Nov 24, 3:30PM CST

IPO: 23.43 (-0.18), BIS: 46.40 (+0.64), BIB: 128.92 (-1.83), IBB: 306.20 (-2.05)

Biotech Weekly: The Value In Beaten-Down Biotech IPOs
Daniel Ward - at Seeking Alpha - Mon Nov 24, 8:26AM CST

ROKA: 3.98 (-0.03), NERV: 4.45 (-0.11), IBB: 306.20 (-2.05), REPH: 2.70 (+0.15)

Are Central Banks Panicking?
Leo Kolivakis - Seeking Alpha - Fri Nov 21, 12:50PM CST
Koh Gui Qing and Jason Subler of Reuters report, China surprises with interest rate cut to spur growth : China cut interest rates unexpectedly on Friday, stepping up efforts to support the world's second-biggest economy as it heads towards its...
PGNX: 7.25 (+0.15), BCRX: 9.92 (-0.66), AVNR: 16.96 (+0.04), ACAD: 30.46 (+0.05), IDRA: 4.06 (-0.01), QQQ: 105.37 (-0.05), SGEN: 36.50 (-0.91), XBI: 178.11 (-1.37), TGTX: 13.84 (-0.58), IBB: 306.20 (-2.05), THLD: 3.00 (+0.05), IWM: 116.81 (-0.56), TWTR: 38.79 (-0.27), XOMA: 4.46 (-0.30)

CB Pharma on deck for IPO
Seeking Alpha - at Seeking Alpha - Fri Nov 21, 10:46AM CST

IPO: 23.43 (-0.18), BIS: 46.40 (+0.64), BIB: 128.92 (-1.83), CNDO: 2.32 (-0.02), IBB: 306.20 (-2.05), DRGS: 54.00 (unch), IXJ: 103.43 (-0.03), IRY: 49.05 (+0.06)

CF Foundation sells royalties for $3.3B
Seeking Alpha - at Seeking Alpha - Thu Nov 20, 7:03AM CST

BIS: 46.40 (+0.64), VRTX: 118.71 (-1.47), BIB: 128.92 (-1.83), IBB: 306.20 (-2.05), DRGS: 54.00 (unch), IXJ: 103.43 (-0.03), IRY: 49.05 (+0.06)

Global drug tab will breach trillion dollar mark this year
Seeking Alpha - at Seeking Alpha - Thu Nov 20, 6:41AM CST

BIS: 46.40 (+0.64), IMS: 25.53 (+0.31), PCYC: 139.90 (+0.57), GILD: 101.82 (+0.94), BIB: 128.92 (-1.83), IBB: 306.20 (-2.05), AMGN: 166.55 (-1.52), DRGS: 54.00 (unch), IXJ: 103.43 (-0.03), IRY: 49.05 (+0.06)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

UWM Faces Class Action Deadline: Key Insights for Investors

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Compass Unveiled: Power Revolution in Private Equity

AI-Driven Insights: Revolutionizing Private Equity Strategies Now this is some spicy news from Huntington Beach! Collective just pulled back the curtain on Compass, their AI-fueled platform that's set to shake up how financial advisors tackle private company equity. If you're an advisor who's sick of staring at nebulous balance sheets filled with unquantifiable private...

GORGIE Unleashes Berry Burst: Target's New Drink Star

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Leapora's Taskeen: Redefining Task Accountability

AI's Impact on Workplace Task Management In today’s whirlwind of AI-generated output, transparency is not just a luxury; it’s a necessity. AI systems churn out work that can appear polished but often lacks substance. This doesn't just create headaches; it triggers a ticking bomb in the regulatory department. According to a 2025 survey from Stanford and BetterUp Labs,...

K-Beauty Takes Front Stage at Target Beauty Studio

Making Waves in the U.S. with K-Beauty SUNGBOON EDITOR and Milk Touch just rolled into Target Beauty Studio, making a splash in the world of K-beauty. From ingredients that boast serious benefits to playful cosmetics that let you express yourself, these brands are shaking up American beauty routines in a big way. Ingredient-Focused Skincare for Every American Face...

MRI Surveillance Gains Ground in Lung Cancer Care

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

The Chemical Industry and EPA: A Broken System?

Decades of an Unchecked Revolving Door The Environmental Protection Agency (EPA) and chemical manufacturers—a dance that’s been going on for what seems like forever. But not in the way you might hope. We're talking about a revolving door where execs and lobbyists waltz into regulatory chairs while regulators slide into cushy industry gigs. Wisner Baum LLP, a stickler...

Sean Trahan Joins Citrin Cooperman: New Tax Lead

Citrin Cooperman's Strategic Tax Move If there's one phrase that can spark a debate at a financial water cooler, it's 'transfer pricing.' Today, Citrin Cooperman is throwing its hat further into that ring with the appointment of Sean Trahan as head of their new Transfer Pricing and Value Chain Optimization Practice. This isn't just another reshuffling of office...

FJBio Boosts Antibody Discovery with Sapio AI

In the sprawling world of antibody discovery, where every scrap of data can make or break the next big breakthrough, FairJourney Bio (FJBio) is pulling out all the stops. They've teamed up with Sapio Sciences to ditch the paperwork nightmares and usher in a new era of AI-driven efficiency. With operations stretching from Porto to Cambridge to sunny San Diego, they’re...

Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...